Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: One-year results

Retina

Volumn 33, Issue 3, 2013, Pages 513-521

  Mimoun, Gérard ^a,b   Caillaux, Violaine ^a   Querques, Giuseppe ^a   Rothschild, Pierre Raphaël ^a   Puche, Nathalie ^a   Souied, Eric H ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b Ophthalmology Imaging Center of Ecole Militaire   (France)

Author keywords

adult onset foveomacular vitelliform dystrophy; anti vascular endothelial growth factor; choroidal neovascularization; fluorescein angiography; indocyanine green angiography; medical retina; optical coherence tomography; ranibizumab

Indexed keywords

FLUORESCEIN; INDOCYANINE GREEN; RANIBIZUMAB;

AGED; ARTICLE; CATARACT; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; DRUG EFFICACY; EYE FUNDUS; EYE INFLAMMATION; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; RETINA DETACHMENT; RETINA MACULA VITELLIFORM DEGENERATION; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; COLORING AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITELLIFORM MACULAR DYSTROPHY;

EID: 84874947629     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182753adb     Document Type: Article

References (28)

1. Gass JDM. A clinicopathology study of a peculiar macular dystrophy. Trans Am Ophthalmol Soc 1974;72:139-156
2. Glacet-Bernard A, Soubrane G, Coscas G. Macular vitelliform degeneration in adults: Retrospective study of a series of 85 patients. J Fr Ophtalmol 1990;13:407-420
3. Puche N, Querques G, Benhamou N, et al. High-resolution spectral domain optical coherence tomography features in adult onset foveomacular vitelliform dystrophy. Br J Ophthalmol 2010;94:1190-1196
4. Brecher R, Bird AC. Adult vitelliform macular dystrophy. Eye 1990;4:210-215
5. Da Pozzo S, Parodi MB, Toto L, Ravalico G. Occult choroidal neovascularization in adult-onset foveomacular vitelliform dystrophy. Ophthalmologica 2001;215:412-414
6. Do P, Ferrucci S. Adult-onset foveomacular vitelliform dystrophy. Optometry 2006;77:156-166
7. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-733
8. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-870
9. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633-642. e4
10. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-372
11. Chang TS, Bressler NM, Fine JT, et al. MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol 2007;125:1460-1469
12. Querques G, Forte R, Querques L, et al. Natural course of adultonset foveomacular vitelliform dystrophy: A spectral-domain optical coherence tomography analysis. Am J Ophthalmol 2011;152:304-313
13. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteprofin for neovascular agerelated macular degeneration. N Eng J Med 2006;355:1432-1444
14. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431
15. Lalloum F, Souied EH, Bastuji-Garin S, et al. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 2010;30:399-406
16. Mimoun G, Tilleul J, Leys A, et al. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. Am J Ophthalmol 2010;150:692-700.e1
17. Parodi MB, Iacono P, Cascavilla M, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy. Invest Ophthalmol Vis Sci 2010;51:4358-4361
18. Querques G, Kerrate H, Leveziel N, et al. Intravitreal ranibizumab for choroidal neovascularization associated with retinal astrocytic hamartoma. Eur J Ophthalmol 2010;20:789-791
19. Querques G, Forte R, Querques L, Souied EH. Intravitreal ranibizumab for choroidal neovascularization associated with circumscribed choroidal hemangioma. Clin Experiment Ophthalmol 2011;39:916-918
20. Liang F, Puche N, Soubrane G, Souied EH. Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch's membrane rupture. Graefes Arch Clin Exp Ophthalmol 2009;247:1285-1288
21. Quijano C, Querques G, Massamba N, et al. Type 3 choroidal neovascularization associated with fundus flavimaculatus. Ophthalmic Res 2009;42:152-154
22. Querques G, Bocco MC, Soubrane G, Souied EH. Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with vitelliform macular dystrophy. Acta Ophthalmol 2008;86:694-695
23. Querques G, Bocco MC, Soubrane G, Souied EH. Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with Stargardt's disease. Graefes Arch Clin Exp Ophthalmol 2008;246:319-321
24. Prieto-Calvo E, Torrón-Fernández Blanco C, Egea-Estopiñán C, et al. Intravitreal ranibizumab for choroidal neovascularisation associated with adult-onset vitelliform dystrophy. Arch Soc Esp Oftalmol 2012;87:149-152
25. Querques G, Azria S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 2010; 94:292-296
26. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583
27. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58
28. CATT Research Group. Martin DF,Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908